

CADTH RAPID RESPONSE REPORT: REFERENCE LIST

# Oral Polysaccharide Iron Complex and Heme Iron Polypeptide for Those Requiring Iron Supplementation: Clinical Effectiveness, Cost-Effectiveness, Safety, and Guidelines

Service Line: Rapid Response Service  
Version: 1.0  
Publication Date: February 26, 2019  
Report Length: 6 Pages

**Authors:** Deba Hafizi, Suzanne McCormack

**Cite As:** *Oral polysaccharide iron complex and heme iron polypeptide for those requiring iron supplementation: clinical effectiveness, cost-effectiveness, safety, and guidelines.* Ottawa: CADTH; 2019 Feb. (CADTH rapid response report: reference list).

**Disclaimer:** The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

**About CADTH:** CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

**Funding:** CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

## Research Questions

1. What is the comparative clinical effectiveness of oral polysaccharide iron complex or heme iron polypeptide versus oral iron salts for iron supplementation?
2. What is the comparative clinical effectiveness of oral polysaccharide iron complex or heme iron polypeptide versus injectable iron supplements for iron supplementation?
3. What is the clinical evidence regarding the safety of oral polysaccharide iron complex or heme iron polypeptide versus injectable iron supplements for iron supplementation?
4. What is the cost-effectiveness of oral polysaccharide iron complex or heme iron polypeptide for iron supplementation?
5. What are the evidence-based guidelines regarding the use of oral polysaccharide iron complex or heme iron polypeptide for iron supplementation?

## Key Findings

Two randomized controlled trials were identified on the clinical effectiveness of oral polysaccharide iron complex and heme iron polypeptide for those requiring iron supplementation. No relevant economic evaluations or evidence-based guidelines were identified.

## Methods

A limited literature search was conducted on key resources including PubMed, the Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. For Q4 and Q5, methodological filters were applied to limit retrieval to economic studies and guidelines. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2015 and February 21, 2019.

## Selection Criteria

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

**Table 1: Selection Criteria**

<b>Population</b>	Anyone requiring iron supplementation in any setting (such as: adults, elderly, children, infants, pregnant people, etc.)
<b>Intervention</b>	Oral polysaccharide iron complex (e.g., Triferexx, Feramax, Jamp Ferrous polysaccharide, Niferex, Polyride-FE); Oral heme iron polypeptide (e.g., Proferrin, Jamp-Iron Polypeptide);

<b>Comparator</b>	Q1,4: Iron salts (ferrous sulfate, ferrous fumarate, ferrous gluconate), or the interventions compared to one another; Q2,3: Injectable iron formulations (such as: iron sucrose, iron dextran, iron sodium ferric gluconate, iron isomaltoside, etc.); Q5: None
<b>Outcomes</b>	Q1,2: Efficacy (improvement in relevant laboratory findings such as: mean corpuscular volume, hemoglobin, ferritin, transferrin saturation, hematocrit, serum iron, total iron binding capacity, red cell distribution width, reticulocyte count, etc.); Q3: Side effects and adverse events (such as: nausea, vomiting, diarrhea, constipation, gastrointestinal upset, epigastric pain, etc.); Q4: Cost-effectiveness, incremental cost per health benefit gained; Q5: Guidelines;
<b>Study Designs</b>	Health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies, evidence-based guidelines

## Results

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials, non-randomized studies, economic evaluations, and evidence-based guidelines.

Two randomized controlled trials were identified on the clinical effectiveness of oral polysaccharide iron complex and heme iron polypeptide for those requiring iron supplementation. No relevant health technology assessments, systematic reviews, meta-analyses, non-randomized studies, or evidence-based guidelines were identified.

Additional references of potential interest are provided in the appendix.

### Health Technology Assessments

No literature identified.

### Systematic Reviews and Meta-analyses

No literature identified.

### Randomized Controlled Trials

#### *Heme Iron versus Iron Salts*

1. Mischler RA, Armah SM, Craig BA, et al. Comparison of Oral Iron supplement Formulations for Normalization of Iron Status Following Roux-EN-y Gastric Bypass Surgery: a Randomized Trial. *Obes Surg.* 2018 Feb;28(2):369-377.  
[PubMed: PM28779269](#)

#### *Iron Polysaccharide Complex versus Iron Salts*

2. Powers JM, Buchanan GR, Adix L, Zhang S, Gao A, McCavit TL. Effect of Low-Dose Ferrous Sulfate vs Iron Polysaccharide Complex on Hemoglobin Concentration in Young Children With Nutritional Iron-Deficiency Anemia: A Randomized Clinical Trial. *JAMA.* 2017 Jun 13;317(22):2297-2304.  
[PubMed: PM28609534](#)

## Non-Randomized Studies

No literature identified.

## Economic Evaluations

No literature identified.

## Guidelines and Recommendations

No literature identified.

## Appendix — Further Information

### Previous CADTH Reports

3. Polysaccharide-iron complex for children with iron deficiency: clinical and cost-effectiveness. (*CADTH rapid response report: summary of abstracts*). Ottawa (ON): CADTH; 2017.  
<https://www.cadth.ca/polysaccharide-iron-complex-children-iron-deficiency-clinical-and-cost-effectiveness-0>
4. Liquid or water soluble polysaccharide-iron complex versus ferrous sulfate for pediatric populations: clinical and cost-effectiveness. (*CADTH rapid response report: summary of abstracts*). Ottawa (ON): CADTH; 2016.  
<https://www.cadth.ca/liquid-or-water-soluble-polysaccharide-iron-complex-versus-ferrous-sulfate-pediatric-populations-0>
5. Oral iron for anemia: a review of the clinical effectiveness, cost-effectiveness and guidelines. (*CADTH rapid response report: summary with critical appraisal*). Ottawa (ON): CADTH; 2016.  
[PubMed: PM26889525](https://pubmed.ncbi.nlm.nih.gov/266889525/)

### Systematic Reviews or Meta-Analyses – Oral Therapy Unspecified

6. Nielsen OH, Ainsworth M, Coskun M, Weiss G. Management of iron-deficiency anemia in inflammatory bowel disease: a systematic review. *Medicine (Baltimore)*. 2015 Jun;94(23):e963.  
<https://www.ncbi.nlm.nih.gov/pubmed/26061331>